PL2021796T3 - Diagnozowanie choroby sercowo-naczyniowej - Google Patents

Diagnozowanie choroby sercowo-naczyniowej

Info

Publication number: PL2021796T3
Authority: PL; Poland
Prior art keywords: cardiovascular disease; diagnosis; bmi; outcome; individuals
Prior art date: 2006-05-01

Application number

PL07761666T

Other languages

English (en)

Inventor

James V Snider

Sven Jacobson

Original Assignee

Critical Care Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-01

Filing date

2007-05-01

Publication date

2012-07-31

2007-05-01 Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc

2012-07-31 Publication of PL2021796T3 publication Critical patent/PL2021796T3/pl

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PL07761666T 2006-05-01 2007-05-01 Diagnozowanie choroby sercowo-naczyniowej PL2021796T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US79691206P	2006-05-01	2006-05-01
EP07761666A EP2021796B1 (en)	2006-05-01	2007-05-01	Diagnosis of cardiovascular disease
PCT/US2007/067914 WO2007130962A2 (en)	2006-05-01	2007-05-01	Diagnosis of cardiovascular disease

Publications (1)

Publication Number	Publication Date
PL2021796T3 true PL2021796T3 (pl)	2012-07-31

Family

ID=38668487

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL07761666T PL2021796T3 (pl)	2006-05-01	2007-05-01	Diagnozowanie choroby sercowo-naczyniowej
PL12152464T PL2482078T3 (pl)	2006-05-01	2007-05-01	Diagnozowanie choroby sercowo-naczyniowej

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL12152464T PL2482078T3 (pl)	2006-05-01	2007-05-01	Diagnozowanie choroby sercowo-naczyniowej

Country Status (13)

Country	Link
US (2)	US10203339B2 (pl)
EP (3)	EP3059594A1 (pl)
JP (5)	JP5377289B2 (pl)
AT (1)	ATE545032T1 (pl)
AU (1)	AU2007248160B2 (pl)
CA (1)	CA2650963C (pl)
DK (2)	DK2021796T3 (pl)
ES (2)	ES2380711T3 (pl)
HU (1)	HUE028594T2 (pl)
PL (2)	PL2021796T3 (pl)
PT (1)	PT2021796E (pl)
SI (1)	SI2482078T1 (pl)
WO (1)	WO2007130962A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002038794A2 (en)	2000-11-09	2002-05-16	The Brigham And Women's Hospital, Inc.	Cardiovascular disease diagnostic and therapeutic targets
WO2003094856A2 (en)	2002-05-09	2003-11-20	The Brigham And Women's Hospital, Inc.	1l1rl-1 as a cardiovascular disease marker and therapeutic target
PL2386860T4 (pl)	2006-04-24	2015-09-30	Critical Care Diagnostics Inc	Przewidywanie śmiertelności i wykrywanie poważnej choroby
US20090305265A1 (en) *	2006-04-27	2009-12-10	Critical Care Diagnostics, Inc.	Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PL2021796T3 (pl)	2006-05-01	2012-07-31	Critical Care Diagnostics Inc	Diagnozowanie choroby sercowo-naczyniowej
ES2542343T3 (es) *	2006-05-02	2015-08-04	Critical Care Diagnostics, Inc.	Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
CN107254517A (zh)	2008-01-18	2017-10-17	哈佛大学校长及研究员协会	在体液中检测疾病或病症标志的方法
EP3093663B1 (en)	2008-04-18	2018-06-13	Critical Care Diagnostics, Inc.	Predicting risk of major adverse cardiac events
WO2010017972A1 (en) *	2008-08-13	2010-02-18	Roche Diagnostics Gmbh	D-dimer, troponin, nt-probnp for pulmonary embolism
EP2336740B1 (en)	2009-12-10	2014-02-12	Emhart Glass S.A.	Method and system for monitoring a glass container forming process
US9671357B2 (en) *	2009-12-10	2017-06-06	Emhardt Glass S.A.	System and method for monitoring hot glass containers to enhance their quality and control the forming process
ES2571994T3 (es) *	2010-04-09	2016-05-27	Critical Care Diagnostics Inc	Anticuerpos contra ST-2 humana soluble y ensayos
AU2011280997A1 (en)	2010-07-23	2013-02-28	President And Fellows Of Harvard College	Methods of detecting autoimmune or immune-related diseases or conditions
EA201390150A1 (ru)	2010-07-23	2013-09-30	Президент Энд Феллоуз Оф Гарвард Колледж	Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
US20130210647A1 (en)	2010-07-23	2013-08-15	President And Fellows Of Harvard College	Methods of Detecting Cardiovascular Diseases or Conditions
KR20130041962A (ko)	2010-07-23	2013-04-25	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
AU2011280936A1 (en)	2010-07-23	2013-02-28	President And Fellows Of Harvard College	Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2609211A1 (en) *	2010-08-27	2013-07-03	University of Zurich	A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
EP3605104B1 (en)	2011-03-17	2021-09-15	Critical Care Diagnostics, Inc.	Methods predicting risk of an adverse clinical outcome
CN106908604B (zh)	2011-07-18	2019-01-29	重症监护诊断股份有限公司	治疗心血管疾病和预测运动疗法功效的方法
CN103748465B (zh) *	2011-08-05	2015-12-09	美艾利尔圣地亚哥公司	监测心衰的方法和试剂
CN104507383B (zh) *	2012-05-18	2018-08-28	重症监护诊断股份有限公司	用于治疗或预报室性快速性心律失常事件风险的方法
US20140179805A1 (en)	2012-06-15	2014-06-26	Harry Stylli	Methods of detecting diseases or conditions
EP2861788B1 (en)	2012-06-15	2018-10-10	Progenity, Inc.	Methods of detecting diseases or conditions using circulating diseased cells
RU2683026C2 (ru)	2012-08-16	2019-03-26	Критикал Кэа Дайэгностикс, Инк.	Способы прогнозирования риска развития гипертензии
WO2014031764A1 (en)	2012-08-21	2014-02-27	Critical Care Diagnostics, Inc.	Multimarker risk stratification
CN104837359B (zh) *	2012-12-14	2018-06-05	希尔氏宠物营养品公司	用于陪伴动物的抗衰老食品
WO2014164366A1 (en)	2013-03-09	2014-10-09	Harry Stylli	Methods of detecting cancer
US11585814B2 (en)	2013-03-09	2023-02-21	Immunis.Ai, Inc.	Methods of detecting prostate cancer
CA2935958A1 (en)	2014-01-10	2015-07-16	Critical Care Diagnostics, Inc.	Methods and systems for determining risk of heart failure
MA40636A (fr)	2014-09-11	2015-09-11	Colleen Kelly	Procédés pour détecter le cancer de la prostate
US10079073B2 (en)	2014-12-11	2018-09-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en)	2014-12-11	2019-06-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4004A (en) *		1845-04-16		Wooden bbidge
US3012A (en) *		1843-03-21		Machine fob
US4208479A (en)	1977-07-14	1980-06-17	Syva Company	Label modified immunoassays
US5206140A (en)	1988-06-24	1993-04-27	Research Corporation Technologies, Inc.	Assay for soluble crosslinked fibrin polymers
US6176962B1 (en)	1990-02-28	2001-01-23	Aclara Biosciences, Inc.	Methods for fabricating enclosed microchannel structures
US5217899A (en)	1990-08-24	1993-06-08	The General Hospital Corporation	Cell stretching apparatus
JP2665850B2 (ja)	1991-11-14	1997-10-22	塩野義製薬株式会社	ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en)	1992-06-03	1992-07-15	Medisinsk Innovation A S	Chemical compounds
JP2732005B2 (ja)	1992-12-14	1998-03-25	眞一富永	ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
JPH0731479A (ja)	1993-02-23	1995-02-03	Shinichi Tominaga	マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en)	1995-03-03	2000-05-23	Millennium Pharmaceuticals, Inc.	Methods for the treatment of immune disorders
WO1998007754A1 (en)	1996-08-23	1998-02-26	Human Genome Sciences, Inc.	T1 receptor-like ligand ii
US20020111472A1 (en)	1997-02-28	2002-08-15	Jian Ni	T1-r ligand iii
DE19711932A1 (de)	1997-03-21	1998-09-24	Anne Katrin Dr Werenskiold	In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
EP2305236A1 (en)	1997-04-02	2011-04-06	The Brigham And Women's Hospital, Inc.	Means of Ascertaining an Individual's Risk Profile for Atherosclerotic Disease
CA2293718A1 (en)	1997-06-10	1998-12-17	Medlyte Diagnostics, Inc.	Methods for early detection of heart disease
CN1161609C (zh)	1997-09-11	2004-08-11	盐野义制药株式会社	哺乳类γ－BNP衍生物特异的免疫测定方法及其试剂盒
US5842787A (en)	1997-10-09	1998-12-01	Caliper Technologies Corporation	Microfluidic systems incorporating varied channel dimensions
GB9727172D0 (en)	1997-12-24	1998-02-25	Univ Glasgow	Reagents specific for st2l and uses therefor
GB9827348D0 (en)	1998-12-12	1999-02-03	Univ Leicester	Natriuretic peptide
AU2055300A (en)	1998-12-18	2000-07-03	Scios Inc.	Methods for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en)	1999-06-02	2000-12-07	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) *	1999-07-01	2001-11-23	Inst Nat Sante Rech Med	Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6323334B1 (en)	1999-09-24	2001-11-27	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en)	2000-03-21	2001-10-03	Takao Arai	Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
US20020115081A1 (en)	2000-08-22	2002-08-22	Lee Richard T.	Diagnosis and treatment of cardiovascular conditions
WO2002038794A2 (en)	2000-11-09	2002-05-16	The Brigham And Women's Hospital, Inc.	Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en)	2000-12-07	2003-03-25	Koninklijke Philips Electronics, N.V.	Strain rate analysis in ultrasonic diagnostic images
US20040253637A1 (en)	2001-04-13	2004-12-16	Biosite Incorporated	Markers for differential diagnosis and methods of use thereof
US7713705B2 (en)	2002-12-24	2010-05-11	Biosite, Inc.	Markers for differential diagnosis and methods of use thereof
EP1322957B1 (en) *	2001-05-04	2009-08-12	Biosite Incorporated	Diagnostic markers of acute coronary syndromes and methods of use thereof
US6905827B2 (en)	2001-06-08	2005-06-14	Expression Diagnostics, Inc.	Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en)	2001-07-26	2003-03-20	Eos Biotechnology, Inc.	Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en)	2001-11-21	2004-10-26	Pacesetter, Inc.	Implantable cardiac stimulation system and method for monitoring diastolic function
WO2003094856A2 (en)	2002-05-09	2003-11-20	The Brigham And Women's Hospital, Inc.	1l1rl-1 as a cardiovascular disease marker and therapeutic target
AU2003239544A1 (en)	2002-05-24	2003-12-12	Tularik Inc.	Amplification and overexpression of oncogenes
US8263325B2 (en)	2002-11-15	2012-09-11	Ottawa Heart Institute Research Corporation	Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
AU2003288027A1 (en) *	2002-11-16	2004-06-15	Dade Behring Marburg Gmbh	Scd40l, papp-a and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases
US20070042978A1 (en)	2002-12-19	2007-02-22	Jean-Philippe Girard	Nf-hev compositions and methods of use
US20040133079A1 (en)	2003-01-02	2004-07-08	Mazar Scott Thomas	System and method for predicting patient health within a patient management system
US20050123451A1 (en)	2003-10-31	2005-06-09	Hiroshi Nomura	System and apparatus for body fluid analysis using surface-textured optical materials
EP2405023B1 (en)	2003-11-26	2014-01-08	Celera Corporation	Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof
US7781219B2 (en)	2003-12-05	2010-08-24	The Cleveland Clinic Foundation	Risk markers for cardiovascular disease
US20050196817A1 (en)	2004-01-20	2005-09-08	Molecular Staging Inc.	Biomarkers for sepsis
NZ549040A (en)	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja)	2004-03-31	2005-10-20	Akira Matsumori	心疾患の検査法
PT1849009E (pt)	2005-01-24	2009-01-14	Hoffann La Roche Ag F	Utilização de hormonas cardíacas para avaliar um risco cardiovascular em relação à administração de fármacos anti-inflamatórios
EP1731910A1 (en)	2005-06-07	2006-12-13	F. Hoffmann-La Roche Ag	Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
JP4820192B2 (ja)	2006-03-17	2011-11-24	一般財団法人化学及血清療法研究所	急性冠症候群でのａｄａｍｔｓ１３の測定と利用
PL2386860T4 (pl)	2006-04-24	2015-09-30	Critical Care Diagnostics Inc	Przewidywanie śmiertelności i wykrywanie poważnej choroby
US20090305265A1 (en)	2006-04-27	2009-12-10	Critical Care Diagnostics, Inc.	Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PL2021796T3 (pl)	2006-05-01	2012-07-31	Critical Care Diagnostics Inc	Diagnozowanie choroby sercowo-naczyniowej
ES2542343T3 (es)	2006-05-02	2015-08-04	Critical Care Diagnostics, Inc.	Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
WO2007130627A2 (en)	2006-05-04	2007-11-15	The Brigham And Women's Hospital, Inc.	Il-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru)	2006-06-14	2007-12-20	Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию"	Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
US20090111708A1 (en)	2007-05-11	2009-04-30	Seddon Johanna M	Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB0713404D0 (en)	2007-07-11	2007-08-22	Integra Sp Ipr Ltd	Altio graph
WO2009040133A1 (en)	2007-09-26	2009-04-02	Universitätsklinikum Heidelberg	Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr)	2007-10-26	2009-11-20	Minima	Lunettes de type sans entourage a branches filaires
EP3093663B1 (en)	2008-04-18	2018-06-13	Critical Care Diagnostics, Inc.	Predicting risk of major adverse cardiac events
JP5584695B2 (ja)	2008-11-11	2014-09-03	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	Ａｄｍ及びｂｎｐのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価
CA2780301A1 (en)	2009-11-13	2011-05-19	Bg Medicine, Inc.	Risk factors and prediction of myocardial infarction
ES2571994T3 (es)	2010-04-09	2016-05-27	Critical Care Diagnostics Inc	Anticuerpos contra ST-2 humana soluble y ensayos
RU2452394C1 (ru)	2010-11-09	2012-06-10	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет	Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
EP3605104B1 (en)	2011-03-17	2021-09-15	Critical Care Diagnostics, Inc.	Methods predicting risk of an adverse clinical outcome
CN106908604B (zh)	2011-07-18	2019-01-29	重症监护诊断股份有限公司	治疗心血管疾病和预测运动疗法功效的方法
CN104507383B (zh)	2012-05-18	2018-08-28	重症监护诊断股份有限公司	用于治疗或预报室性快速性心律失常事件风险的方法
RU2683026C2 (ru)	2012-08-16	2019-03-26	Критикал Кэа Дайэгностикс, Инк.	Способы прогнозирования риска развития гипертензии
WO2014031764A1 (en)	2012-08-21	2014-02-27	Critical Care Diagnostics, Inc.	Multimarker risk stratification
CA2935958A1 (en)	2014-01-10	2015-07-16	Critical Care Diagnostics, Inc.	Methods and systems for determining risk of heart failure
US9934249B2 (en)	2014-06-03	2018-04-03	Conduent Business Machines Services, Llc	Systems and methods for context-aware and personalized access to visualizations of road events
US10079073B2 (en)	2014-12-11	2018-09-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en)	2014-12-11	2019-06-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker

2007
- 2007-05-01 PL PL07761666T patent/PL2021796T3/pl unknown
- 2007-05-01 CA CA2650963A patent/CA2650963C/en not_active Expired - Fee Related
- 2007-05-01 EP EP15198075.2A patent/EP3059594A1/en not_active Withdrawn
- 2007-05-01 SI SI200731749A patent/SI2482078T1/sl unknown
- 2007-05-01 AT AT07761666T patent/ATE545032T1/de active
- 2007-05-01 PL PL12152464T patent/PL2482078T3/pl unknown
- 2007-05-01 DK DK07761666.2T patent/DK2021796T3/da active
- 2007-05-01 WO PCT/US2007/067914 patent/WO2007130962A2/en not_active Ceased
- 2007-05-01 PT PT07761666T patent/PT2021796E/pt unknown
- 2007-05-01 AU AU2007248160A patent/AU2007248160B2/en not_active Ceased
- 2007-05-01 DK DK12152464.9T patent/DK2482078T3/en active
- 2007-05-01 EP EP07761666A patent/EP2021796B1/en not_active Not-in-force
- 2007-05-01 EP EP12152464.9A patent/EP2482078B1/en not_active Not-in-force
- 2007-05-01 HU HUE12152464A patent/HUE028594T2/en unknown
- 2007-05-01 ES ES07761666T patent/ES2380711T3/es active Active
- 2007-05-01 JP JP2009510021A patent/JP5377289B2/ja not_active Expired - Fee Related
- 2007-05-01 US US12/299,177 patent/US10203339B2/en active Active
- 2007-05-01 ES ES12152464.9T patent/ES2566169T3/es active Active
2012
- 2012-04-26 JP JP2012101238A patent/JP5467120B2/ja not_active Expired - Fee Related
2014
- 2014-01-27 JP JP2014012149A patent/JP5676789B2/ja not_active Expired - Fee Related
- 2014-12-25 JP JP2014261824A patent/JP6008933B2/ja not_active Expired - Fee Related
2016
- 2016-09-13 JP JP2016178188A patent/JP6470717B2/ja not_active Expired - Fee Related
2018
- 2018-12-17 US US16/221,673 patent/US20190120852A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2021796B1 (en)	2012-02-08
US10203339B2 (en)	2019-02-12
PT2021796E (pt)	2012-04-19
JP6470717B2 (ja)	2019-02-13
ES2380711T3 (es)	2012-05-17
EP3059594A1 (en)	2016-08-24
US20100009356A1 (en)	2010-01-14
EP2482078A1 (en)	2012-08-01
JP6008933B2 (ja)	2016-10-19
WO2007130962A2 (en)	2007-11-15
WO2007130962A3 (en)	2008-09-04
US20190120852A1 (en)	2019-04-25
EP2021796A2 (en)	2009-02-11
EP2021796A4 (en)	2009-10-28
AU2007248160B2 (en)	2011-03-24
ES2566169T3 (es)	2016-04-11
SI2482078T1 (sl)	2016-05-31
DK2482078T3 (en)	2016-05-02
CA2650963C (en)	2020-09-15
JP2009535649A (ja)	2009-10-01
JP2014095724A (ja)	2014-05-22
JP5377289B2 (ja)	2013-12-25
JP5676789B2 (ja)	2015-02-25
DK2021796T3 (da)	2012-05-29
JP2015064384A (ja)	2015-04-09
AU2007248160A1 (en)	2007-11-15
ATE545032T1 (de)	2012-02-15
JP5467120B2 (ja)	2014-04-09
PL2482078T3 (pl)	2016-08-31
CA2650963A1 (en)	2007-11-15
JP2012163572A (ja)	2012-08-30
HUE028594T2 (en)	2016-12-28
EP2482078B1 (en)	2016-02-03
JP2016218084A (ja)	2016-12-22

Publication	Publication Date	Title
PL2482078T3 (pl)	2016-08-31	Diagnozowanie choroby sercowo-naczyniowej
WO2005114190A3 (en)	2010-01-07	Methods of identifying biomarkers
WO2008084331A3 (en)	2009-04-23	Biomarkers for renal disorders
ITRM20050265A1 (it)	2006-11-28	Protesi modulare perfezionata per osteosintesi, in particolare per l'osteosintesi dell'omero.
EP2486924A3 (en)	2013-01-09	Drugs and uses
WO2007061906A3 (en)	2007-07-12	Diagnostic and therapeutics for cardiovascular disorders
JP2006511520A5 (pl)	2006-12-14
WO2006134390A3 (en)	2007-04-19	Method for diagnosing neurodegenerative disease
WO2008061149A3 (en)	2008-10-30	Methods and compositions for diagnosis and prognosis of renal artery stenosis
BRPI0510224A (pt)	2007-10-23	métodos de prevenção de doença autoimunológica e artigo industrializado
WO2009029971A8 (en)	2009-05-14	Method for diagnosing the metabolic syndrome (ms)
GB0514501D0 (en)	2005-08-24	Pharmaceutical compounds
WO2007033513A3 (de)	2007-05-31	Schiefes tourbillon
WO2004024167A3 (fr)	2004-05-13	Utilisation de prebiotiques, preferentiellement le glucooligosaccharide, pour la prevention de l’installation du diabete de type ii
EP1870710A4 (en)	2008-09-17	BIOMARKERS FOR DIAGNOSIS OF DISEASE AND USE THEREOF
WO2003088811A3 (en)	2004-02-26	Gelsolin as a prognostic marker of artherosclerotic diseases
WO2008057966A3 (en)	2008-07-03	A panel of biomarkers for peripheral arterial disease
BRPI0515727A (pt)	2008-08-05	biomarcador para insuficiência cardìaca
WO2006074405A3 (en)	2007-12-21	Pecam-1 genotype
Luzhnikov et al.	2004	Assessment of the Severity of Acute Clozapine(Azaleptine) Poisonings from the Position of Clinical Toxicometry
WO2005093091A3 (en)	2006-02-09	Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2009063254A3 (en)	2009-11-12	Thymidine kinase assay
WO2006005470A3 (en)	2006-07-20	Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2007009704A3 (en)	2007-04-19	Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
Kageyama	2005	Last trend of micro-mechanics and failure analysis of composite materials(I) DSCan fracture mechanics be used for strength design of composite materials?